

Original Article

Surveillance of current antibiotic resistance among clinical isolates *S. aureus*, *E. coli* and *P. aeruginosa* collected from five Iranian cities

Open Access

Reza Hosseini Doust^{1*}, Mehdi Saberi², Mohamad Javad Hosseini³, Ashraf Mohabati Mobarez⁴

1. Department of Microbiology, Faculty of Advance Sciences and Technology, Islamic Azad University-Pharmaceutical Sciences Branch (IAUPS), Tehran/Iran

2. Department of Pharmacology, Baqiyatallah University of Medical Sciences (BUMS), Tehran/Iran

3. Research Center of Molecular Biology, Baqiyatallah University of Medical Sciences (BUMS), Tehran/Iran

4. Department of bacteriology, Faculty of Medical Sciences, Tarbiat Modares University (TMU), Tehran/Iran

Abstract

Antibiotic resistance is an emerging problem worldwide present in many bacteria, specially *S. aureus*, *P. aeruginosa*, and *E. coli* that are consider as the most common group of bacteria responsible for nosocomial infections. This problem would be more serious and divesting in developing countries where there is not regular surveillance program for periodic antibiotic resistance. In attempts to report the antibiotic pattern in Iranian cities, we collected clinical isolates and tested them against current antibiotics. 653 Clinical isolates of *S. aureus*, *P. aeruginosa*, and *E. coli* were collected during 5 months. The isolates were then transported to research laboratory within glycerol containing medium. Standard antibiotic discs containing different concentrations of each agent were provided from MAST media. Standard disc diffusion method was carried out and the result was interpreted using NCCLS tables and data charts. Isolates were mostly cultured from respiratory, Urine, wounds, blood clinical samples. The clinical isolates were *E. coli* (45%) *S. aureus* (33%), and *P. aeruginosa* (22%). 20% of *E. coli*, 9% of *P. aeruginosa*, and 12% of *S. aureus* isolates showed reduction of sensitivity to Amikacin (AK). 27% of *S. aureus* had reduction of sensitivity to Vancomycin (VA). About 25% of *P. aeruginosa* showed reduced sensitivity to Gentamicin (GM).

Key words: Antibiotic resistance, Amikacin, Vancomycin, Gentamicin, *S. aureus*, *P. aeruginosa*, *E. coli*, Iran

*Correspondence to: Professor Reza Hosseini Doust, Prof. of Microbiology, Department of Microbiology, Faculty of Advanced Sciences and Technology, Islamic Azad University, Pharmaceutical Sciences Branch (IAUPS), P.O. Box: 18395-6466, Tel: +98 21 22640051-5 (EX 320), Fax: +98 21 22600099, Email address: rhdoust@iaups.ac.ir

1. Introduction

Antibiotic resistance is an emerging problem worldwide present in many bacteria. Nosocomial infections occurs worldwide and affect both developed and resource poor countries. The most common group of bacteria responsible for nosocomial infections are *Staphylococcus aureus*, *Pseudomonas aeruginosa*, and *Escherichia coli*. The emergence of resistant strains has increased the morbidity and mortality associated with infections of different human organs especially; urinary tracts, trauma, burns, wounds, respiratory tracts, sepsis (Syeda et al. 2010, Goswami et al. 2011).

P. aeruginosa is an epitome of opportunistic nosocomial pathogen, which causes a wide spectrum of infections and leads to substantial morbidity in immuno compromised patients (Lee et al. 2009). Despite therapy the mortality due to Nosocomial, *Pseudomonas pneumonia* is approximately 70%.(Castre et al. 2000). Unfortunately, *P. aeruginosa* developed resistance to most of antibiotics thereby jeopardizing the selection of appropriate treatment (Obritsch et al. 2004). The *S. aureus* strains are beginning to develop resistance to vancomycin in different regions of the world. the emergence of VRSA/VISA (*Vancomycin resistant Staphylococcus aureus/vancomycin intermediate Staphylococcus aureus*) might also be prevalent as antibiotic misuse is equally common (Tiwari et al. 2006). *E. coli* has high percentages of resistance to ampicilline, thrimethoprim-sulfamethoxazole, tetracycline, chloramphenicol and nalidixic acid, which implies important complications in antibiotic treatment when required (Giacometti et al. 2000). *Escherichia coli* represents an incredible versatile and diverse enterobacterial species and can be subdivided into the following; (i) intestinal non-pathogenic, commensal isolates. (ii) Intestinal pathogenic isolates and (iii) extraintestinal pathogenic *E. coli* or ExPEC isolates (Goswami 2011).

They are three most frequent nosocomial infection, associated with increased hospital stay, costs, and use of antimicrobial agents (Mangram et al. 1999). Antibiotic resistance can be controlled by appropriate antimicrobial prescribing, prudent infection control, new treatment alternatives, and continued surveillance (Ducel et al. 2001). The increasing antibiotic resistance is due to the acquisition of different molecular mechanisms of resistance through point chromosomal mutations and / or horizontal transfer of genetic material between related or different species facilitated by some genetic elements such as integrons (Weber et al. 2009). Risk factors other than microbiology can be due to systemic factors affecting the patient's healing response, local wound characteristics, or operative characteristics. Its risk depends on bleeding, the amount of devitalized tissue created, the need for drains within the wound, obesity and diabetes mellitus (Suchitra et al. 2009). Due to significant changes in microbial genetic ecology, as a result of indiscriminate use of anti-microbials, the spread of antimicrobial resistance is now a global problem (Schmitz et al. 1999). Present study was preliminary designed to find out the antibiotic susceptibility patterns of *P. aeruginosa*, *S. aureus*, and *E. coli* clinical isolates collected from different major cities in Iran.

2. Materials and methods

Different strains of *P. aeruginosa*, *S. aureus*, and *E. coli* were isolated from clinical samples collected within each city's medical laboratory during last periods of 2011. The isolated were characterized and microbiologically identified at the species level in original laboratory prior shipment to central research laboratory in Tehran. All strains were transported to destination within in glycerol containing media and through standard circumstances.

The isolates were then recovered on standard laboratory media (Sheep Blood Agar and EMB agar) for each species and reconfirmed their preliminary identification. The tablets and standard discs containing different concentrations of Amikacin (AK), Ampicilin (AMP), Cefotaxime (CTX), Cefpirome (CEP), Ceftazidime (CAZ), Ceftriaxone (CRO), Cephazolin (CZ), Cloramphenicol (CL), Ciprofloxacin (CIP), Clindamycin (CD), Cloxacillin (CX), Gentamicin (GM), Imipenem (IM), Tazobactam /Piperacillin (PTZ), Vancomycin (VA) were purchased

from MAST Media (MAST, UK. LTD), and were kept according the manufacturer instruction until use. Standard disc diffusion method (Kerbi-Byer disc diffusion method) was carried out and the result was interpreted using National Committee for Clinical Laboratory Standards (NCCLS) tables and data charts (Wkler et al. 2005). The resistance isolates were then subjected to MIC tests, according to supplier’s manual.

3. Results




Figure 1: Comparison clinical sources of isolates

The isolates were obtained from different Clinical samples
Isolates were mostly cultured from respiratory,

Urine, wounds, blood, CSF, stool by; 34%, 22%, 21%, 15%, 3.7%, and 3.4% respectively. Totally 653 isolates were subjected to experimental analysis in our study, which

Table 1: Distribution of isolates through origin cities of collection

spp	Ahvaz	Mashad	Shiraz	Tabriz	Tehran	Total
<i>P. aeruginosa</i>	76	41	24	22	63	216
<i>S. aureus</i>	16	72	25	16	12	143
<i>E. coli</i>	108	36	26	27	96	294
Total	200	148	75	67	163	653

were contributed almost equally by five cities located in north, center and south of nationwide

The clinical isolates were commonly identified as *E. coli* (45%) *S. aureus* (33%), and *P. aeruginosa* (22%).

More than 60% of *E. coli* were sensitive to Amikacin (AK) and 20% were resistant to it, 20% of isolates showed reduction of sensitivity. 50% of *E. coli* were sensitive to Ampicilin (AMP), and 20% were resistant to

(AMP), remaining isolates showed reduction of sensitivity. 54% of *E. coli* were sensitive and 46% were resistant to Cefotaxime (CTX). 62% were sensitive to Ciprofloxacin (CIP), the of remaining isolates showed reduction of sensitivity. 70% were sensitive to Cloramphenicol (CL) and 30% were resistant to it, remaining isolates showed reduced of sensitivity. (GM), 55% of *E. coli* were sensitive to Gentamicin (GM) and 25% were resistant to it, remaining isolates showed




Figure 2: Pattern of antibiotic resistance in *E. coli* isolates

reduction of sensitivity. 81% of *E. coli* were resistant to Imipenem (IM), the remaining isolates showed reduction of sensitivity

About 54% of *P. aeruginosa* were sensitive to, and 37% were resistant to Amikacin (AK), 9% of isolates showed reduction of sensitivity. 40% were sensitive, and 40% were resistant to Ampicilin (AMP), the remaining isolates showed reduction of sensitivity. *P. aeruginosa* (54%) were sensitive and 46% were resistant Cefotaxime (CTX). 33% were sensitive and 61% were resistant Ceftazidime (CAZ), the remaining 6% showed reduction of sensitivity.

(CIP), 24% of *P. aeruginosa* were sensitive to Ciprofloxacin (CIP), 39% were resistance, and the remaining isolates showed reduction of sensitivity. Cloramphenicol (CL) sensitivity was about 70% within *P. aeruginosa* isolates, while 30% were resistant, and the remaining isolates showed reduction of sensitivity. 75% of were sensitive to Gentamicin (GM), and remaining isolates were resistance. Imipenem (IM) sensitivity was at least 68% among *P. aeruginosa* isolates, and remaining were resistance or reduced the sensitivity to IM. Tazobactam /Piperacillin (PTZ) affected




Figure 3: Pattern of antibiotic resistance in P. aeruginosa isolates

successfully on 37% of isolates, while 44% were resistant to it, and the remaining isolates showed some degree of sensitivity reduction. More than 58% of S. aureus were sensitive to Amikacin (AK) and 20% were resistant to it, and 12% of isolates showed reduction of sensitivity. 50% of isolates were sensitive and 20% were resistant Ampicillin (AMP), the remaining isolates showed reduction of sensitivity. Cefotaxime (CTX), 54% of S. aureus were sensitive to CTX and 46% were resistant to it. Ciprofloxacin (CIP); 62% of S. aureus were sensitive to CIP the remaining isolates showed reduction of sensitivity.

Clindamycin (CD); 63% of S. aureus were sensitive to CL and 30% were resistant to it, remaining isolates showed reduction of sensitivity. Cloramphenicol (CL); 70% of S. aureus were sensitive to CL and 30% were resistant to it. Cloxacillin (CX); 16% of isolates were sensitive to CL and 84% were resistant to it. Gentamicin (GM); 45% of S. aureus were sensitive to GM and 30% were resistant, remaining isolates showed reduction of sensitivity. Imipenem (IM); 81% of S. aureus were resistant to IM, and the remaining isolates showed reduction of sensitivity. About




Figure 4: Pattern of antibiotic resistance in S. aureus isolates

60% of isolates were sensitive and 13% were resistant to Vancomycin (VA), remaining isolates showed reduction of sensitivity

4. Discussion

The aim of present study was to survey sensitivity pattern of clinical isolates of three major causes of nosocomial infections. Bacterial isolates were mostly cultured from clinical samples such as respiratory secretions, urinary tracts, wounds, and blood. Although the wide spectrum of gram positive and gram negative bacteria were isolated from clinical samples, and interesting information produced (data not shown), but our logic emphasize was on *E. coli*, *P. aeruginosa*, and *S. aureus*. *E. coli* was the most organism isolated followed by *P. aeruginosa*, and *S. aureus*; while the predominant isolates was subject to changes from sample to sample. Similar findings were observed in previous studies where percentage of gram negative bacilli from the wounds was more, and coagulase positive *Staphylococcus* was predominant organism (Rubin et al. 2006). We observed reduction of sensitivity within *Staphylococcus aureus* to Amikacin (12%), Ampicilin (30%), Ciprofloxacin (38%), Clindamycin (7%), Gentamicin (25%), Imipenem (19%), and Vancomycin (27%). It is essential for clinical laboratories to screen for and confirm vancomycin resistance in the clinical laboratory

Incidence of vancomycin resistance *S. aureus* (VRSA) in our study was slightly higher than previously reported data of India. (Tiwari and Sen 2006). This should be cautiously interpreted as this might be because of false positive result by other species (Tiwari and Sen 2006). Other study also shows false positive result by using same disc diffusion method (Hiramatsu et al. 1977) studied that *Staphylococcus aureus* was also capable of transformation into the homogenously resistant strains and adhering to artificial surfaces, The BSAC (British Society for Antimicrobial Chemotherapy) has standardized method for disc diffusion testing

to evaluate vancomycin susceptibility for MRSA isolates. (Howe et al. 1999). There is a need for the modern day clinical laboratory to develop a definitive method to confirm hetero-resistance to vancomycin among MRSA isolates as this could direct antibiotic therapy. However, there is need for active VRSA surveillance by healthcare institutions in India to enforce infection control measures, rational use of antibiotics and to prevent development of further resistance against this organism (Lyer et al. 2008).

In the present study, *Pseudomonas aeruginosa* showed reduced sensitivity to commonly used antibiotics such as Amikacin, Ampicilin, Cephotoxime, and ciprofloxacin. It is more and less, in agreement to previously published reports (Lee et al. 2011, Burnham et al. 2010). Ciprofloxacin has been stated to be the most potent drug available for the treatment of *P. aeruginosa* infections (Chastre et al. 2000, Obritsch et al 2004). This report is in conformity with the result of our study in which ciprofloxacin resistance was 39% among *P. aeruginosa* isolates from wound infection patients. Similar reduced resistance of *P. aeruginosa* to ciprofloxacin has been reported in Jamaica, Latin America, Nigeria and in Malaysia (Abu hanifa 1990, 24). It is undoubtable that at the present time, ciprofloxacin is the most effective antibiotics against *P. aeruginosa* involved in wound infection relative to most other commonly used drugs (Zhanel et al. 2008). Periodic susceptibility testing should be carried out over a period of two to three years to detect the resistance trends (Andrews 2001). Also, a rational strategy on the limited and prudent use of antipseudomonal agents is urgently required. In fact, the irrational and inappropriate use of antibiotics is responsible for the development of resistance of *Pseudomonas* species to antibiotic monotherapy. *Pseudomonas* resistant to carbapenem and third generation cephalosporins is real threat (Gales et al. 2001).

The incidence of *P. aeruginosa*, *S. aureus* and *E. coli* in Nosocomial and postoperative

wound infection is becoming more serious in developing countries because of relaxation in general hygienic measures, production of low quality antiseptic, and medicinal solutions for treatment, difficulties in proper definition of the responsibility among the hospital staff (Fadeyi and Akanbi 2005). Lack of uniform antibiotic policy and indiscriminate use of antibiotics may have led to emergence of resistant bacterial strains. Particularly pseudomonas resistance to third generation cephalosporin and meropenem and VRSA/VISA are real threat to control hospital acquired infection (Ducel et al 2001). Hence, there should be an immediate response from the concerned authorities to check further emergence and spreading of these notorious VRSA strains and also there is a need to emphasize the rational use of antimicrobials and strictly adhere to the concept of “reserve drugs” to minimize the misuse of available antimicrobials (Schmitz et al. 1999). Here is an alarming increase of infections caused by antibiotic-resistant bacteria. Further studies are required to check the results provided in this study before final conclusion. In addition, regular antimicrobial susceptibility surveillance is essential for area-wise monitoring of the resistance patterns. Sensitivity pattern of *E. coli* in our study confirmed the work of Syeda et al. as the sensitivity of Ciprofloxacin was 62% vs. 62.7%, and for Ampicillin was 50 vs. 51.2 (Syeda et al. 2010), but they were considerably less than information reported by Goswami et al. as 62 vs. 87-100 for Ciprofloxacin, and 50 vs. 83-84 for Ampicillin (Goswami et al. 2011). Interestingly, strains isolated from wounds infections were sensitive to CIP, CX, GM, and IM. An effective national and state level antibiotic policy and draft guidelines should be introduced to preserve the effectiveness of antibiotics and for better patient management.

5. Acknowledgment

This project was supported by the research grant from ministry of health and medical education of Iran. The authors are thankful to authorities and technicians of collaborator laboratories in the cities where the preliminary experiments were carried out.

Conflict of interests : None declared.

6. References

- Abu Hanifah Y. Post-operative surgical wound infection. *Med J Malaysia*. 1990; 45: 293–7.
- Andrews JM. The development of the BSAC standardized method of disc diffusion testing. *J Antimicrob Chemother*. 2001; 48: 29–42.
- Burnham CA, Weber CJ, Michael WM., Jr Novel Screening Agar for Detection of Vancomycin- Nonsusceptible *Staphylococcus aureus*. *J Clin Microbiol*. 2010; 48: 949–51.
- Chastre J, Trouillet JL. Problem pathogens (*Pseudomonas aeruginosa* and *Acinetobacter*) *Semin Respir Infect*. 2000;15:287–98.
- Ducel G, Fabry J, Nicolle L. Prevention of hospital-acquired infections: A practical guide. World Health Organization, Department of Communicable Disease, Surveillance and response. 2nd ed. 2005.
- Fadeyi A, Akanbi AA, 2nd, Nwabuisi C, Onile BA. Antibiotic disc sensitivity pattern of *Pseudomonas aeruginosa* isolates obtained from clinical specimen in Ilorin, Nigeria. *Afr J Med*. 2005; 34: 303–6.
- Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of *Pseudomonas aeruginosa*: occurrence rate, antimicrobial susceptibility pattern and molecular typing in the global sentry antimicrobial surveillance program 1997-1999. *Clinic Infect Dis*. 2001; 32: S146–55.

- Giacometti A, Cicrioni O, Schimizzi AM, Delprete MS, Barchiesi F, D'Errico MM, et al. Epidemiology and Microbiology of Surgical Wound infections. *J Clin Microbiol.* 2000; 38: 918–22.
- Goswami NN, Trivedi HR, Goswami AP, Patel TK, Tripathi CB. Antibiotic sensitivity profile of bacterial pathogens in postoperative wound infections at a tertiary care hospital in Gujarat, India. *J Pharmacol Pharmacother.* 2011; 2 (3):158-64.
- Goswami NN, Trivedi HR, Goswami AP, Patel TK, Tripathi CB. Antibiotic sensitivity profile of bacterial pathogens in postoperative wound infections at a tertiary care hospital in Gujarat, India. *J Pharmacol Pharmacother.* 2011 1; 2(3): 158-64.
- Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hori S, Hosoda Y, et al. Dissemination in Japanese Hospitals of strains of *Staphylococcus aureus* heterogeneously resistant to vancomycin. *Lancet.* 1997; 350: 1670–3.
- Howe RA, Wootton M, Bennett PM, Mac Gowan AP, Walsh TR. Interactions between methicillin and vancomycin in methicillin resistant *Staphylococcus aureus* strains displaying different phenotypes of vancomycin susceptibility. *J Clin Microbiol.* 1999; 37: 3068–71.
- Iyer RN, Hittinahalli V. Modified PAP method to detect heteroresistance to vancomycin among methicillin resistant *Staphylococcus aureus* isolates at a tertiary care hospital. *Indian J Med Microbiol.* 2008; 26: 176–9.
- Lee K, Kim MN, Kim JS, Hong HL, Kang JO, Shin JH, Park YJ, Yong D, Jeong SH, Chong Y; KONSAR Group. Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of *Acinetobacter* spp. and *P. aeruginosa* in Korea: KONSAR study 2009. *Yonsei Med J.* 2011;52(5):793-802.
- Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection. *Infect Control Hosp Epidemiol.* 1999; 20: 250–78.
- Obritsch MD, Fish DN, McLaren R, Jung R. National Surveillance of Antimicrobial Resistance in *Pseudomonas aeruginosa* isolates obtained from Intensive Care Unit Patients from 1993 to 2002. *Antimicrob Agents Chemother.* 2004; 48:4606–10.
- Rubin RH. Surgical wound infection: Epidemiology, pathogenesis, diagnosis and management. *BMC Infect Dis.* 2006; 6: 171.
- Schmitz FJ, Fluit AC, Gondolf M, Beyrau R, Lindenlauf E, Verhoef J, et al. The prevalence of aminoglycoside resistance and corresponding resistance genes in clinical isolates of *Staphylococci* from 19 European hospitals. *J Antimicrob Chemother.* 1999; 43:253–9.
- Suchitra JB, Lakshmi N. Surgical site infections. Assessing risk factors and antimicrobial sensitivity patterns. *Afr J Microbiol Res.* 2009; 3: 185–9.
- Syeda Q, Ali, 1 Ale Zehra,1. Baquar S. Naqvi,1 Shahjahan Shah,1 and Rabia Bushra. Resistance Pattern of Ciprofloxacin Against Different Pathogens. *Oman Med J.* 2010; 25(4): 294–298.
- Tiwari HK, Sen MR. Emergence of vancomycin resistant *Staphylococcus aureus* from a tertiary care hospital from northern part of India. *BMC Infect Dis.* 2006; 6:156.
- Weber SG, Miller RR, Perenevich EN, Tolentino J, Meltzer D, Pitrak D, et al. Prevalence of antimicrobial resistant bacteria isolated from older versus younger hospitalized adults: Results of a two centre study. *J Antimicrob Chemother.* 2009; 64: 1291–8.
- Wkler Mathew A, Cockerill Franklin R,

Bush Karen, Dudley Michael N, Etiopoule George M, Hardy Dhright J, et al. Clinical and laboratory standard institute. Performance standards for an antimicrobial disc susceptibility tests; Approved standard. 10th ed., 2005

Zhanel GG, DeCorby M, Laing N, Weshnoweski B, Vashisht R, Tailor F. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. *Antimicrob Agents Chemother.* 2008; 52: 1430–7.